全文获取类型
收费全文 | 107944篇 |
免费 | 6904篇 |
国内免费 | 447篇 |
专业分类
耳鼻咽喉 | 1201篇 |
儿科学 | 2773篇 |
妇产科学 | 1983篇 |
基础医学 | 13573篇 |
口腔科学 | 1936篇 |
临床医学 | 11532篇 |
内科学 | 21748篇 |
皮肤病学 | 1409篇 |
神经病学 | 10636篇 |
特种医学 | 4115篇 |
外国民族医学 | 3篇 |
外科学 | 17476篇 |
综合类 | 1238篇 |
一般理论 | 139篇 |
预防医学 | 8984篇 |
眼科学 | 2213篇 |
药学 | 6873篇 |
中国医学 | 110篇 |
肿瘤学 | 7353篇 |
出版年
2023年 | 591篇 |
2022年 | 971篇 |
2021年 | 2204篇 |
2020年 | 1394篇 |
2019年 | 2209篇 |
2018年 | 2656篇 |
2017年 | 1928篇 |
2016年 | 2092篇 |
2015年 | 2397篇 |
2014年 | 3587篇 |
2013年 | 4965篇 |
2012年 | 7865篇 |
2011年 | 8327篇 |
2010年 | 4755篇 |
2009年 | 4284篇 |
2008年 | 7425篇 |
2007年 | 7739篇 |
2006年 | 7471篇 |
2005年 | 7169篇 |
2004年 | 6958篇 |
2003年 | 6336篇 |
2002年 | 5960篇 |
2001年 | 1095篇 |
2000年 | 868篇 |
1999年 | 1132篇 |
1998年 | 1320篇 |
1997年 | 1010篇 |
1996年 | 833篇 |
1995年 | 763篇 |
1994年 | 677篇 |
1993年 | 657篇 |
1992年 | 634篇 |
1991年 | 596篇 |
1990年 | 480篇 |
1989年 | 467篇 |
1988年 | 445篇 |
1987年 | 460篇 |
1986年 | 385篇 |
1985年 | 437篇 |
1984年 | 419篇 |
1983年 | 337篇 |
1982年 | 396篇 |
1981年 | 356篇 |
1980年 | 287篇 |
1979年 | 194篇 |
1978年 | 216篇 |
1977年 | 152篇 |
1976年 | 141篇 |
1975年 | 114篇 |
1973年 | 135篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Zhenzhen Zhang Mark Garzotto Tomasz M. Beer Philippe Thuillier Stephen Lieberman Motomi Mori 《Nutrition and cancer》2016,68(8):1309-1319
Animal and human studies suggest fish oil and green tea may have protective effect on prostate cancer. Fatty acid synthase (FAS) has been hypothesized to be linked to chemoprotective effects of both compounds. This study evaluated the independent and joint effects of fish oil (FO) and green tea supplement (epigallocatechin-3-gallate, EGCG) on FAS and Ki-67 levels in prostate tissue. Through a double-blinded, randomized controlled trial with 2 × 2 factorial design, 89 men scheduled for repeat prostate biopsy following an initial negative prostate biopsy were randomized into either FO alone (1.9 g DHA + EPA/day), EGCG alone (600 mg/day), a combination of FO and EGCG, or placebo. We used linear mixed-effects models to test the differences of prostate tissue FAS and Ki-67 by immunohistochemistry between pre- and post-intervention within each group, as well as between treatment groups. Results did not show significant difference among treatment groups in pre-to-post-intervention changes of FAS (P = 0.69) or Ki-67 (P = 0.26). Comparing placebo group with any of the treatment groups, we did not find significant difference in FAS or Ki-67 changes (all P > 0.05). Results indicate FO or EGCG supplementation for a short duration may not be sufficient to produce biologically meaningful changes in FAS or Ki-67 levels in prostate tissue. 相似文献
3.
4.
Mark Koday DDS Stephen Davis DDS Molly Melbye DDS MPH 《Journal of public health dentistry》2020,80(Z2):S114-S116
The Yakima Valley Farm Workers Clinic (YVFWC) is one of the largest community health centers in the country with clinics throughout south-central Washington and northern Oregon. Its dental program consists of 14 dental clinics providing general and specialty services to the low-income populations it serves. Modeling itself after the YVFWC medical managed care program; the Dental program recently added value-based metrics to its dental practice after Oregon offered a value-based dental reimbursement plan in 2019. This is the first-step YVFWC's dental program that has taken to prepare for value-based reimbursement and transform its dental practice in order to reduce the disease burden in its patient population. The purpose of this article is to describe the processes YVFWC undertook to prepare itself for the new reimbursement model, which included the development of metrics, a metric validation process, a clinical dashboard, and a method for improving metrics. It also outlines its medical/dental integration improvement brought about by embedding hygienists into the medical primary care teams. 相似文献
5.
6.
7.
8.
9.
10.
Mark Verrill 《Surgery (Oxford)》2019,37(3):181-185
Multimodality primary therapies for breast cancer combined with earlier detection have led to a sharp decline in the death rate from breast cancer in the UK over the last 40 years in the face of a rising incidence. The latest UK statistics from Cancer Research UK report 55,122 new cases of breast cancer in 2015 with 11,563 deaths from breast cancer recorded in 2016. Crudely, this equates to a cure rate of around 80% for all comers and demonstrates a clear improvement in outcome with 50,285 new cases in 2011 and 11,716 deaths in 2012. Despite this good news, there are still significant numbers of women (and men) who suffer from either a local recurrence or metastatic disease following apparently successful treatment for early breast cancer (Stage I to III). Only a minority of individuals, 6.6% with the stage recorded at diagnosis, present with stage IV disease. This review considers the treatment options available to individuals with locally recurrent and advanced breast cancer (ABC). 相似文献